Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1

References

• World Health Organization. Fact sheets: cancer 2018. World Health Organization; 2018. https://www.who.int/en/news-room/fact-sheets/detail/cancer
   Google Scholar
• World Health Organization. Cancer Today. World Health Organization; 2022. https://gco.iarc.fr/today/home
   Google Scholar
• American Cancer Society. Lung cancer statistics | How common is lung cancer?. American Cancer Society; 2022. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html
   Google Scholar
• Paz-Ares L, Luft A, Vicente D, KEYNOTE-407 Investigators, et al. Pembrolizumab plus chemotherapy for squamous Non-Small-Cell lung cancer. N Engl J Med. 2018;379(21):2040–2051.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Langer CJ, Paz-Ares L, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: a pooled analysis of 3 randomized controlled trials. Cancer. 2020;126:4867–4877.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, IMpower133 Study Group, et al. First-Line atezolizumab plus chemotherapy in Extensive-Stage Small-Cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, ESMO Guidelines Committee, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21.
   PubMed Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti G V, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–3559.
   PubMed Web of Science ®Google Scholar
• Chouaid C, Atsou K, Hejblum G, et al. Economics of treatments for non-small cell lung cancer. Pharmacoeconomics. 2009;27:113–125.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Annex 1 – summary of product characteristics – atezolizumab 2021. European Medicines Agency; 2021.
   Google Scholar
• Felip E, Altorki N, Zhou C, IMpower010 Investigators, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344–1357.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health. 2022;25:10–31.
   PubMed Web of Science ®Google Scholar
• Ortega Eslava A, Marín Gil R, Fraga Fuentes MD, et al. Incluye actualización del área económica del programa madre 4.0. proyecto de investigación financiado mediante las ayudas a los grupos de la sefh 2014-15. Autores: guía Práctica. Grupos de trabajo SEFH SociedaEspañola de Farmacia Hospitalaria (SEFH). 2016.
   Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía Para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–170.
   PubMed Web of Science ®Google Scholar
• Puig-Junoy J, Oliva-Moreno J, Trapero-Bertrán M, et al. Guía y recomendaciones Para la realización y presentación de evaluaciones económicas y análisis de impacto presupuestario de medicamentos en el ámbito del CatSalut. Barcelona: Generalitat de Catalunya Departament de Salut Servei Català de la Salut; 2014.
   Google Scholar
• Nakamichi S, Horinouchi H, Asao T, et al. Comparison of radiotherapy and chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer developing after surgery. Clin Lung Cancer. 2017;18:e441–e448.
   PubMed Web of Science ®Google Scholar
• Kruser TJ, McCabe BP, Mehta MP, et al. Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol. 2014;37(1):70–76.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–2301.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
   PubMed Web of Science ®Google Scholar
• Jang RW, Isogai PK, Mittmann N, et al. Derivation of utility values from european organization for research and treatment of cancer quality of Life-Core 30 questionnaire values in lung cancer. J Thorac Oncol. 2010;5(12):1953–1957.
   PubMed Web of Science ®Google Scholar
• Chouaid C, Agulnik J, Goker E, et al. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8:997–1003.
   PubMed Web of Science ®Google Scholar
• van den Hout WB, Kramer GWPM, Noordijk EM, et al. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2006;98(24):1786–1794.
   PubMedGoogle Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF). Base de datos del Consejo General de Colegios Oficiales de Farmacéuticos. 2022. www.portalfarma.com
   Google Scholar
• De Castro J, Insa A, Collado-Borrell R, et al. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulm Med. 2023;23(1):69.
   PubMed Web of Science ®Google Scholar
• Remon J, Soria JC, Peters S, ESMO Guidelines Committee. Electronic address: [email protected]. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637–1642.
   PubMed Web of Science ®Google Scholar
• Ortega-Joaquin N, Echave M, Oyagüez I, et al. Cost-Analysis for toxicity management in advanced squamous Non-Small cell lung cancer: nivolumab vs docetaxel. Value in Health. 2016;19:a722.
   Web of Science ®Google Scholar
• Gisbert R, Brosa M. Healthcare cost database eSalud. Barcelona; 2022. http://www.oblikue.com/bddcostes/
   Google Scholar
• Nuño-Solinís R, Herrera Molina E, Librada Flores S, et al. Care costs and activity in the last three months of life of cancer patients who died in the Basque Country (Spain). Gac Sanit. 2017;31:524–530.
   PubMed Web of Science ®Google Scholar
• INE. Instituto Nacional de Estadística 2022. https://ine.es/
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500.
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27:746–761.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. ¿Qué es una intervención sanitaria eficiente en españa en 2020? Gac Sanit. 2020;34:189–193.
   PubMed Web of Science ®Google Scholar
• Loh J, Wijaya ST, Sooi K, et al. Resectable non-small cell lung cancer: an evolving landscape. Transl Lung Cancer Res. 2022;11:1241–1246.
   PubMed Web of Science ®Google Scholar
• Zhou K, Zhao Y, Liang L, et al. Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: a propensity score-matched analysis. Front Oncol. 2022;12:938195.
   PubMed Web of Science ®Google Scholar
• Mithoowani H, Febbraro M. Non-Small-Cell lung cancer in 2022: a review for general practitioners in oncology. Curr Oncol. 2022;29:1828.
   PubMed Web of Science ®Google Scholar
• Shukla N, Hanna N. Neoadjuvant and adjuvant immunotherapy in Early-Stage Non-Small cell lung cancer. Lung Cancer. 2021;12:51–60.
   PubMed Web of Science ®Google Scholar
• Duan J, Tan F, Bi N, et al. Expert consensus on perioperative treatment for non-small cell lung cancer. Transl Lung Cancer Res. 2022;11:1247–1267.
   PubMed Web of Science ®Google Scholar
• de Scordilli M, Michelotti A, Bertoli E, et al. Targeted therapy and immunotherapy in Early-Stage Non-Small cell lung cancer: current evidence and ongoing trials. Inter J Mol Sci. 2022;23:7222.
   PubMed Web of Science ®Google Scholar
• Szeto CH, Shalata W, Yakobson A, et al. Neoadjuvant and adjuvant immunotherapy in Early-Stage Non-Small-Cell lung cancer, past, present, and future. J Clin Med. 2021;10(23):5614.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, O’Brien MER, Mauer M, et al. VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15–PEARLS/KEYNOTE-091 study. Ann Oncol. 2022;33:451–453.
   Google Scholar
• Chaft JE, Dahlberg SE, Khullar O V, et al. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). 2018;36:TPS8581–TPS8581.
   Google Scholar
• Peters S, Kim AW, Solomon B, et al. IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Ann Oncol. 2019;30:II30.
   Google Scholar
• Tsuboi M, Luft A, Ursol G, et al. 1235TiP perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: the phase III KEYNOTE-671 study. Ann Oncol. 2020;31:S801–S802.
   Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, CheckMate 816 Investigators, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985.
   PubMed Web of Science ®Google Scholar
• Das M, Ogale S, Johnson A, et al. EP04.01-017 Cost-Effectiveness of atezolizumab for adjuvant treatment of patients with stage II-IIIA PD-L1+ non-small cell lung cancer. J Thorac Oncol. 2022;17: S253.
   Web of Science ®Google Scholar
• Chen P, Yang Q, Li Y, et al. Cost-effectiveness analysis of adjuvant therapy with atezolizumab in chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy. Front Oncol. 2022;12:4678.
   Web of Science ®Google Scholar